Unlearn.AI, which has built a machine learning platform that creates"digital twin" profiles of patients in clinical trials, has raised $15 million to expand partnerships and accelerate regulatory approval, the company told Reuters on Tuesday. The investment from Radical Ventures and Wittington Ventures valued the startup at $265 million, the company said.
While generative AI is known for creating content like text, images, and even computer code, Unlearn uses it to build digital twins to speed up clinical drug trials through its neural networks. The funding Unlearn raised came after it won approval from the European Medicines Agency in September for using its AI-driven approach for conducting smaller and quicker clinical trials and struck several multi-million dollar deals with pharmaceutical companies, including Merck. San Francisco-based Unlearn focuses on a relatively novel application of generative AI.
關門大吉
Technology Technology Latest News, Technology Technology Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »